Literature DB >> 25595929

Management of severe ulcerative colitis.

Neeraj Narula1, Bindia Jharap, Jean-Frederic Colombel.   

Abstract

OPINION STATEMENT: Acute severe steroid-refractory ulcerative colitis (ASUC) provides challenges for physicians and surgeons who manage these patients. When a patient is diagnosed with ASUC, they should be admitted for inpatient management including intravenous corticosteroids, venous thromboembolism prophylaxis, oral or enteral feeding if tolerated, and exclusion of infection including Clostridium difficile. Failure to improve by day 3 of corticosteroids requires escalation to medical rescue therapies such as infliximab or cyclosporine, or surgical management with colectomy. This chapter will review management of ASUC with a focus on the medical rescue options available.

Entities:  

Year:  2015        PMID: 25595929     DOI: 10.1007/s11938-014-0036-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  84 in total

1.  Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.

Authors:  Gilaad G Kaplan; Ellen P McCarthy; John Z Ayanian; Joshua Korzenik; Richard Hodin; Bruce E Sands
Journal:  Gastroenterology       Date:  2008-01-10       Impact factor: 22.682

2.  Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.

Authors:  Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

3.  Postoperative complications and mortality following colectomy for ulcerative colitis.

Authors:  Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan
Journal:  Clin Gastroenterol Hepatol       Date:  2011-07-30       Impact factor: 11.382

4.  Ciclosporin use in acute ulcerative colitis: a long-term experience.

Authors:  Simon Campbell; Simon Travis; Derek Jewell
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 2.566

5.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

6.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

7.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

8.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

9.  Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.

Authors:  H Yuhara; C Steinmaus; D Corley; J Koike; M Igarashi; T Suzuki; T Mine
Journal:  Aliment Pharmacol Ther       Date:  2013-04-02       Impact factor: 8.171

10.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.